

Invitation



Pfizer is constantly exploring opportunities for partnerships and invites you to submit a research collaboration proposal for the **1st Pfizer Biotech Partnering Days** on October 4–5, 2016 in Berlin.

Your non-confidential proposals will be reviewed by the respective Pfizer Research Teams and those fitting Pfizer's research objectives will be invited to present their work and engage in discussion with Pfizer scientists. The event itself consists of two phases: a presentation of cutting-edge findings by innovation teams selected for the excellence of their work, as well as one-on-one meetings between the presenters and scientists from Pfizer focused on a specific field of research. This is an opportunity to highlight the excellence and expertise of European research to Pfizer and to support the competitiveness of Europe at a global level. Companies outside of Germany are also encouraged to submit research proposals.

As one of the world's leading biopharmaceutical companies, Pfizer is proud to offer you access to our world-class research scientists, our global network of external research collaborations, and our industry-leading clinical development, regulatory, manufacturing and commercial capabilities. Combining your science, tools and technologies with Pfizer's expertise could hold the key to breakthrough therapies for patients worldwide. In our

opinion it is vital to collaborate in new and dynamic ways in order to continue to expedite the pace of innovation.

To participate, you are asked to complete an online application form with regard to our areas of interest (please see below). This will give our scientific committee at Pfizer an idea of the activity and profile of your company/innovation team. We are looking for **ongoing** projects from drug discovery to clinical stage. The preliminary application will consist of a non-confidential, one-page summary including the therapeutic hypothesis, a brief description of the novel target, assay, asset, technology or product, the current status of development and why it could be beneficial to Pfizer. Submissions must be made electronically via www.berlinresearchlab.de. The Pfizer expert panel will then review the proposals against pre-defined criteria and invite a certain number of applicants to participate in the **1st Pfizer Biotech Partnering Event** in Berlin.

Areas of interest for the first event are as follows (Please consult our **R&D brochure** for additional information):

Oncology and associated technologies

- Lung, colorectal, breast, ovarian, GI, bladder, and hematologic cancers
- Targets and technologies that enable antibody and ADC approaches
- Epigenetics
- Small molecule immuno modulators
- Technologies that deliver drugs asymmetrically to specific tissues
- Targeted nanoparticle technologies and assets
- Immuno-Oncology:
 - Novel targets for overcoming tumor-induced immune Resistance
 - Cell-based therapies
 - Bispecific antibodies
 - Oncolytic viruses
 - Personalized vaccines
 - Platform technologies: Mechanisms, biomarkers, and screening approaches to identify and accelerate the most promising IO combination therapies
 - New modalities to induce immune responses: Bi-specific mAbs, nanoparticles, oncolytic viruses, tumor vaccines, chimeric antigen receptors (CARs), or novel T cell receptors (TCRs)
- Identification of new immune modulating targets
- Monitoring of immune-supporting and immune-suppressing biomarkers within the tumor as well as of the anti-tumor immune responses
- Novel animal models that accurately recapitulate human tumor-immune system interactions

Proposals may be submitted by interested legal entities (enterprises, research institutions and universities) located in Germany or in other European countries. The event is not open to service providers or consultants.

Proposals must be submitted until **31-Aug-2016**.

We are looking forward to your proposals!

Submissions must be made electronically via www.berlinresearchlab.de

If you have any questions, please contact info@pfizer.de or +49 30 550055 01

